El Cytoxan se utiliza para tratar ciertos tipos de los siguientes canceres: linfoma, mieloma múltiple, leucemia, micosis fungoides, neuroblastoma, cáncer de ovario, cáncer ocular y cáncer de mama. Generalmente se utiliza junto con otros medicamentos. También puede utilizarse para tratar ciertos problemas renales (síndrome nefrótico) en niños.
Nuestra página de facturación está certificada por:
Cyclophosphamide drug makes the bone marrow more tumor-friendly - News-Medical.net
Cyclophosphamide drug makes the bone marrow more tumor-friendlyNews-Medical.
Docs Need Primer on Long-Term Effects of Chemotherapy - Family Practice News Digital Network
Family Practice News Digital NetworkDocs Need Primer on Long-Term Effects of ChemotherapyFamily Practice News Digital NetworkOnly 6% of primary care physicians were able to identify the main long-term effects (LEs) of doxorubicin (Adriamycin), paclitaxel (Taxol), oxaliplatin (Eloxatin), and cyclophosphamide (Cytoxan), compared with 65% of oncologists surveyed.
ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule ... - MarketWatch (press release)
ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule .
Clinical Conundrums - Clinical Oncology News
Clinical Oncology NewsClinical ConundrumsClinical Oncology NewsTrue or False: In the SWOG S0016/CALGB 50102 trial for patients with previously untreated FL, inferior outcomes were observed with maintenance rituximab versus tositumomab/ 131 I-tositumomab (CHOP-RIT; GlaxoSmithKline) following cyclophosphamide, .
Diffuse Large B-Cell Lymphoma: Current Treatment Approaches - Cancer Network
Diffuse Large B-Cell Lymphoma: Current Treatment ApproachesCancer NetworkWhile a series of trials support R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus rituximab)-21 as the standard of care for all patients, DLBCL has substantial biological and clinical heterogeneity, leading to marked differences .